צמיחת הכנסות ב-12 חודשים נגררים: kiorapharma.com (KPRX)

Kiora Pharmaceuticals (KPRX) maintains a monopoly position in the rare eye pathology niche, supported by patents and FDA status. The relative change in rolling year revenue compared to the same period last year demonstrates revenue dynamics, where the -100.30 level captures the latest values. The company's prospects depend on the success of small molecule clinical trials, while resilience to macro cycles ensures stable demand for innovation.
פילוחי נתונים אנליטיים מרוכזים עבור Kiora Pharmaceuticals Inc. (KPRX)

This indicator measures revenue dynamics over the last twelve months relative to the same period last year, allowing for an assessment of the actual business scaling speed amid market volatility. Analyzing the rolling 12-month sales growth rate year-over-year is critical for Kiora Pharmaceuticals (KPRX), as a sharp upward curve following the completion of ophthalmology drug trials will signal a transition from costly development to the ultra-high margins of solution scaling.